Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP

Withdrawn before enrolling · Not applicable

Conditions studied: Community-acquired Pneumonia

In brief

This is a prospective interventional study to assess laboratory testing which will identify the microbial cause of pneumonia. This, in turn, will allow targeted antimicrobial agent selection for patients with community acquired-pneumonia (CAP). Hypothesis: 1) To determine if Targeted strategy is non-inferior to Empiric therapy with respect to outcome endpoints. 2) To assess the use of innovative POC tests allows targeted narrow-spectrum antimicrobial therapy. 3) To determine if Targeted strategy is superior to Empiric therapy in patients with viral pneumonia

Key facts

Study ID

NCT01662258

Run by

University of Pittsburgh

People needed

0

Starts

2012-10-01

Expected to finish

2013-08-01

Last updated by the study team

2016-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ● Adult patients greater than age 17 years who are initially evaluated in the ED with symptoms of CAP. This includes those who will be treated as outpatients and those admitted to the hospital (both ward and ICU).
• The definition of CAP is as follows:
• Presence of pulmonary infiltrates on chest radiography. (Initial reading may be performed by the ED physician - but has to be confirmed by board certified radiologist for inclusion in the study).
• At least 2 of the following: new onset of cough, productive sputum, shortness of breath, chest pain, fever > 380C, abnormal chest auscultation, WBC > 12,000 cells/mL.
• Able to provide informed consent
• Read, signed, and dated informed consent document
• Available for follow-up for the planned duration of the study

You may not qualify if…

• Patients with underlying immunosuppressive illness (HIV, neutropenia, asplenia, transplant recipient, cystic fibrosis, receipt of immunosuppressive medications including corticosteroids, (equivalent of prednisone > 10 mg) cancer chemotherapy, or anti-tumor necrosis factor agents.
• Patients residing in long-term care facilities

Where it is running

• University of Louisville — Louisville, Kentucky, United States
• Johns Hopkins — Baltimore, Maryland, United States
• Beth Israel — New York, New York, United States
• Summa Health System — Akron, Ohio, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.